References · 469 abstracts cited in narrative

Alphabetical by ControlNumber. Each abstract links back to the chapters/landscapes/topics that cite it.

AB#76 · SC3613 (IN-207387), a mutant-selective EGFR degrader, exhibits potent anti-tumor activity and improv
AB#143 · PBI-381, a development candidate PROTAC for KRasG12D solid tumors
AB#149 · Trogocytosis-orchestrated CLDN18.2-dressed CD8⁺ T cells drive pancreatic cancer progressi
AB#174 · Large language models for tumor genomic interpretation
AB#183 · Attitudes and perception of artificial intelligence in healthcare: A cross-sectional survey among Ar
AB#185 · AI vs human abstraction of pain scores and analgesic trends in low-dose radiation therapy for osteoa
AB#227 · MUC5AC expression defines an immune-inflamed but functionally restrained tumor microenvironment in p
AB#230 · Multi-agent AI system for autonomous CAR-T development: Integrated target discovery, toxicity predic
AB#239 · Amivantamab restores antitumor immunity in non-small cell lung cancer through EGFR/MET expression-de
AB#248 · sB7-H3 as a prognostic biomarker in osteosarcoma: Insights into clinical outcomes
AB#254 · Novel tumor microenvironment (TME) activated interleukin-2 (IL-2) fused to anti-PD-1 or anti-PD-1/VE
AB#301 · IDH mutations disable the tumor suppressive activity of GSX2 to promote gliomagenesis
AB#354 · Engaged but not degraded: Proteome-wide CETSA in degrader research
AB#413 · Albumin-based DLL3-targeted nano-immunoconjugates of SN38 preserve potency and demonstrate high-affi
AB#464 · LY4584180, a novel BCL6 molecular glue, demonstrates antitumor efficacy in preclinical models of B C
AB#510 · A first-in-class IKZF1/3 degrader antibody conjugate (DAC) as a potential myeloma treatment
AB#545 · GenerAItive: An AI system for interpretation of gene expression analyses in cancer
AB#546 · MiR-362-3p enhances platinum response in breast cancer
AB#555 · Dual inhibition of PIKfyve and FASN reveals therapeutic potential in neuroendocrine prostate cancer
AB#572 · A decade-ahead signal of lung cancer from circulating exosomal sncRNAs
AB#577 · Neuroendocrine-like dedifferentiation mediates resistance to EGFR inhibitors via the NRG1/HER3 axis
AB#596 · Nanobody-based, DLL3-directed FAST-CAR T-cell therapy for small cell lung cancer (SCLC)
AB#688 · A multicenter, prospective validation of an AI-based software (PanClaudinAI) for predicting claudin
AB#691 · DS-2243a, an HLA-A*02/NY-ESO-directed bispecific T‑cell engager, shows potent anti-tumor activ
AB#692 · Multi-omic characterization of imaging invisible prostate tumors reveals microenvironmental drivers
AB#706 · Identification of TROP2 as an adaptive resistance mechanism in KRAS G12C inhibition and its therapeu
AB#726 · A comprehensive LLM-enabled pharmacodynamic biomarker resource to accelerate cancer drug development
AB#764 · Arkangel AI, OpenEvidence, ChatGPT, Medisearch: Are they objectively up to medical standards? A real
AB#796 · Plasma proteomics for risk prediction of lung cancer
AB#803 · Preclinical efficacy of DLL3 targeted CAR T cells in neuroblastoma
AB#822 · Generative genomics accurately predicts cancer gene expression
AB#825 · The combination of the AR PROTAC AZD9750 and AKT inhibitor capivasertib delivers improved efficacy o
AB#864 · BGB-21447, a next-generation Bcl-2 inhibitor, demonstrates superior potency and overcomes Venetoclax
AB#872 · Matrix softness and fluid shear forceact through TRPV4 to promote ovarian cancer stemness, tumorigen
AB#890 · HJ-004, a potent and selective pan-EGFR mutation targeted protein degrader (TPD) that effectively ov
AB#895 · HDM2024: A novel EGFR and HER3 bispecific antibody-drug conjugate exhibits superior antitumor activi
AB#1014 · Ovarian cancer survival in the era of targeted treatment: A nationwide study in Germany
AB#1018 · Discovery of potent and selective TRIB2 inhibitors with therapeutic efficacy in therapy-resistant ne
AB#1019 · Targeting AhR suppresses the generation of amivantamab-lazertinib-induced drug-tolerant persisters i
AB#1075 · Rationally designed allosteric EGFR degrader SC3499 (IN-207375) selectively eliminates mutant EGFR a
AB#1078 · Molecularly-informed prediction of treatment efficacy in the GENIE BPC NSCLC cohort using computatio
AB#1081 · AM109, a PSMA×CD137 bispecific antibody with target-dependent T cell activation and potent anti
AB#1118 · A unified prostate cancer single-cell atlas reveals molecular subtypes and lineage plasticity across
AB#1128 · Genomic determinants of PIK3CA mutation driven breast cancer initiation
AB#1132 · Discovery of PLX-66140, a first-in-class, potent and selective CDK2 molecular glue degrader for CCNE
AB#1254 · Development and evaluation of a novel high affinity PSMA-targeted radioligand¹⁷⁷Lu-PSMA-3
AB#1265 · Rational design of potent androgen receptor degraders via AI-assisted molecular modeling and validat
AB#1279 · Local indicators of spatial association bioinformatics analysis identifies animmunosuppressive zone
AB#1292 · LPD002, a novel anti-PD-1/IL-2 fusion protein, demonstrates potent antitumor activity in preclinical
AB#1293 · Comparison of machine learning-based dimensionality reduction methods for dietary patterns and their
AB#1334 · Molecular genetic profiling of a de novo neuroendocrine prostate cancer in a patient-derived
AB#1338 · Single-cell intercellular CRISPR screen reveals stromal regulators of colorectal cancer plasticity
AB#1368 · Ancestry-linked, stage-specific delay to tertiary care is associated with survival differences in co
AB#1378 · Lauren subtype classification in gastric cancer using deep learning on real-world H&E images
AB#1400 · Accurate prediction of microsatellite instability-high gastric cancer from H&E-stained whole sli
AB#1408 · GLAST (SLC1A3), a novel therapeutic target for overcoming osimertinib resistance in lung cancer
AB#1411 · ZEB1 expression in NEUROD1-positive and combined YAP1-dominant pulmonary neuroendocrine carcinomas i
AB#1433 · Effect of the KRAS G12C inhibitor MK-1084 on circulating tumor DNA levels in participants with KRAS
AB#1439 · CEACAM5/6+ cancer cell and IL1B+ macrophage-mediated resistance in anti-PD-1 treated gastric cancer
AB#1535 · ORM-1153: A novel CD123-targeting degrader antibody conjugate with proprietary GSPT1 degrading paylo
AB#1585 · NL019: A next-generation TROP2/NECTIN4 dual-target nanobody-based ADC developed from the NanoOne&#84
AB#1591 · Preclinical characterization of XB773, a novel anti-DLL3 antibody-drug conjugate
AB#1605 · Interleukin-6 increases glucocorticoid inactivation in a castration resistant prostate cancer cell l
AB#1610 · Characterization of CGT1263, a KRAS (ON/OFF) inhibitor clinical candidate with selectivity for mutan
AB#1626 · Minimal-length CAG repeats in AR define a hyperactive AR-LSD1 axis driving metabolic reprogramming i
AB#1630 · Multiplexed spatial profiling of the tumor microenvironment in syngeneic mouse models using Cell DIV
AB#1692 · Development of a novel PSCA-targeting antibody-drug conjugate with high potency and stability for pr
AB#1711 · ²²⁵Ac-RAX104: A novel PSMA-targeted radioligand optimized for actinium-225 demonstra
AB#1801 · GFH603: A molecular glue-like allosteric activator of the KEAP1-CUL3 E3 ligase complex for targeting
AB#1849 · Integrated single-cell analysis identifies biomarkers associated with clinical benefit in patients w
AB#1865 · Deciphering the molecular links between DNA damage response and autophagy in cancer: Implications fo
AB#1888 · Bispecific antibody with dual-payload ADC for metastatic castration-resistant prostate cancer
AB#1900 · Unlocking pMHC target space for next generation T cell engagers in oncology and autoimmunity
AB#1921 · Delta-like ligand 3 (DLL3)-based enrichment enables sensitive and specific detection of circulating
AB#1940 · Discovery of AZD4956, a potent and selective inhibitor of DNA polymerase theta, a clinical candidate
AB#1961 · Early‑onset colorectal and pancreatic cancer in the United States: Incidence and mortality pro
AB#1971 · Automating clinical and pathological staging for breast cancer patients
AB#1997 · An agentic AI workflow for automated, high-fidelity curation of cancer diagnosis and staging from un
AB#2071 · Deep-learning CT biomarker improves early efficacy detection in simulated randomized phase II NSCLC
AB#2075 · Development and clinical evaluation of ⁶⁴Cu-RAX301: A next-generation PSMA PET tracer fo
AB#2142 · ImmunoVerse-Chat: A conversational agentic-AI engine for next-generation immunotherapeutic target di
AB#2197 · QED-203, a dual TRPV6 and AR small molecule preclinical candidate for advanced prostate cancer resis
AB#2228 · Discovery and characterization of XNW34017, a first-in-class, orally bioavailable, and brain-penetra
AB#2255 · QSP modeling to inform dose and regimen selection for TAK-280: A bi-specific antibody
AB#2264 · Genie-ADLA: A deep learning algorithm for methylation-based multiple cancer early detection (MCED)
AB#2307 · Preclinical efficacy and safety of CS5007, an EGFR×HER3 dual-targeting antibody-drug conjugate
AB#2323 · AI-accelerated discovery of B7-H3 and DLL3-targeted cyclic peptide radioligands: From library design
AB#2327 · Preclinical efficacy and safety of CS5008, a novel SSTR2×DLL3 bispecific antibody-drug conjugat
AB#2332 · MAIT engagers: Avoiding Treg suppression to deliver stronger activity in solid tumors.
AB#2335 · Anti-human CTLA-4×TIGIT bispecific antibody: A novel immunotherapy specifically targeting tumor
AB#2337 · Epigenetic profiling identifies markers of aggressive cancer subtype using a targeted methylation-ba
AB#2361 · A rapid patient-derived organoids platform guides the evaluation of ERBB-targeting bispecific T-cell
AB#2376 · Preclinical evaluation of a cardiosafe first-in-class MCL-1 degrader for the treatment of hematologi
AB#2397 · Comparative evaluation of ²²⁵Ac-PSMA-Trillium with other ²²⁵Ac-PSMA-SMOL asset
AB#2429 · GSK5471713: A novel, selective oral androgen receptor degrader with best-in-class potential for the
AB#2437 · Targeted delivery of suicide gene to tumor cells using PD-L1-targeted extracellular vesicles for can
AB#2447 · Structure-guided design of JZY3032, a dual-engaging DALTAC that miswires AR-p300 in prostate cancer
AB#2455 · CBX-663, a first-in-class TCR-mimetic T-Cell Engager targeting the TERT peptide-HLA complex, mediate
AB#2459 · Implementation of a diffusion-based color checker for histological image batch correction
AB#2470 · Comparison of digital and artificial intelligence (AI)-computational algorithms for quantifying low/
AB#2475 · ETX-929, a potential best-In-class, oral, highly potent and selective dual ON / OFF state Pan-KRAS s
AB#2484 · Differential in vitro activity of amivantamab, cetuximab, and panitumumab against EGFR ECD re
AB#2493 · Dual modality of EpiTAC bispecific degrader ADCs combines c-MET degradation with cytotoxic payload d
AB#2500 · Reasoning‑guided retrieval improves oncology trial eligibility matching from clinical notes
AB#2501 · Evaluation of imaging-based prognostication (IPRO) using artificial intelligence (AI) in stage IV co
AB#2502 · Targeting NAMPT using Novel Inhibitor RPT-E-037 in Pancreatic Neuroendocrine Tumor
AB#2508 · Evaluation of ²¹²Pb-PSMA radioligand therapy in an immunocompetent prostate cancer mo
AB#2540 · XmAb808, a B7H3-targeted CD28 bispecific antibody, costimulates T cells enhancing the anti-tumor act
AB#2587 · ETX-880, a potential best-in-class, oral, highly potent and selective covalent inhibitor of Werner h
AB#2699 · Intra-tumoral Porphyromonas gingivalis mediates osimertinib resistance in EGFR-mutant lung ad
AB#2704 · Evidence of noncontiguous haplotype patterns at chromosome band 13q12 associated with prostate cance
AB#2711 · ISM6166, a novel oral pan-KRAS (ON/OFF) inhibitor discovered with generative AI shows robust anti-tu
AB#2714 · Mechanistic insights into the anti-tumor activity of ²¹²Pb-PSMA radioligand therapy
AB#2752 · Maximizing high-risk incidental pulmonary nodule referrals using artificial intelligence
AB#2760 · Enabling phenotypic high-throughput drug screening with patient-derived organoids
AB#2810 · First disclosure of a highly potent and selective oral KRAS G12V inhibitor PSTA-6208
AB#2839 · Exploring viral influence on susceptibility to retinoblastoma in northern Tanzania, The ENVISION-Tan
AB#2892 · From single H&E to virtual immunohistochemical biomarker staining in the lung tumor microenviron
AB#2911 · CADM1-CAR T cells targeting neuroendocrine subtypes of small cell lung cancer
AB#2937 · Discovery and optimization of XTX601, a masked claudin 18.2-targeting T cell engager
AB#3008 · Native domain-interaction rewiring collapses the AR neo-enhanceosome in prostate cancer
AB#3010 · Cbl-b inhibition with ISM3830 restores innate and adaptive immunity and demonstrates antitumor activ
AB#3026 · Preclinical evaluation of a novel hyperbolic NAMPT inhibitor in combination with pan-RAS targeted th
AB#3064 · AZD4956, a potent and selective inhibitor of DNA polymerase theta, enhances the activity of DNA-dama
AB#3068 · From bench to bedside: A CNS penetrant and Omnipotent EGFR inhibitor, WSD0922-FU targeting primary m
AB#3111 · Exceptionally selective and orally bioavailable p300 degraders for the treatment of CBP-mutant and p
AB#3142 · The selective YAP/TEAD inhibitor TY-1054 enhances the efficacy of KRAS inhibitors or Trop2-ADC in mu
AB#3153 · First-in-class CHK1 inhibitor antibody-drug conjugate overcomes limitations of current ADC payloads
AB#3203 · Foundation model-derived features from immunohistochemistry correlate with recurrence and stage in M
AB#3216 · Evaluation of an agentic LLM chatbot for clinico-genomic analysis of AACR GENIE BPC data
AB#3226 · Feasibility and challenges of oral cancer screening in a large healthcare system
AB#3233 · Early-onset colorectal cancer detection through a non-invasive label-free electrochemical immunosens
AB#3240 · Multi-site development of automated lesion classification for comprehensive tumor burden assessment:
AB#3285 · Bridging histopathology and spatial transcriptomics for comprehensive tumor microenvironment profili
AB#3289 · A next-generation CD8-selective tri-specific T cell engager targeting CDH17 with enhanced efficacy a
AB#3304 · Foundation model-based gastric cancer staging from complete, uncurated EGD image sequences
AB#3321 · Preclinical evaluation of GFH276 monotherapy and combination therapy for RAS-mutant tumors
AB#3346 · DLL3-targeted in vivo CAR-T therapy of small cell lung cancer with lipid nanoparticles and ci
AB#3362 · GFS784, a next-generation ADC with a novel panRAS(ON) inhibitor payload
AB#3365 · Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) impairs cellular viability, affects ene
AB#3390 · CWH43 emerges as a novel therapeutic target linked to chemoresistance in colorectal cancer
AB#3393 · SCR-A014, a novel bispecific ADC targeting B7H3 and DLL3 for SCLC therapy, exhibits potent anti-tumo
AB#3397 · D3S-003, an orally bioavailable potent and selective dual-state inhibitor targeting both GDP- and GT
AB#3398 · HEC228032, an orally bioavailable molecular glue pan-RAS (ON) inhibitor with highly potent anti-tumo
AB#3406 · GS24-B047, a potential best-in-class DLL3-targeting T-cell engager with integrated costimulatory sig
AB#3426 · Hydrophilicity-enhanced linker technology enables site-specific degrader-antibody conjugates with im
AB#3469 · JS212, a novel bispecific ADC targeting EGFR and HER3, demonstrates superior and broad antitumor act
AB#3481 · IL-1 alpha expression induces drug resistance to all generations of EGFR inhibitors in HNSCC
AB#3488 · A cleavable IL10-TCE counteracts TCE-induced T cell dysfunction and eradicates solid tumors without
AB#3516 · DAC-1522: A novel Trop2-targeting degrader-antibody conjugate for precision oncology
AB#3520 · Discovery of SY-14556, a highly potent and selective small molecule reactivator of p53 Y220C mutant
AB#3522 · Discovery and characterization of once in a month intravenous and orally bioavailable SMARCA2 degrad
AB#3548 · First-in-human clinical pharmacokinetic prediction of D3S-003, an orally bioavailable dual-state KRA
AB#3585 · The EGFR-PROTAC molecule TY-2719 attenuates acquired resistance to 3rd-generation EGFR TKIs and augm
AB#3597 · Dual targeting of CEACAM6 and EGFR with a bispecific antibody induces EGFR degradation and overcomes
AB#3615 · The MET/HER3 antibody-drug conjugate with dual payload: A dual-target approach to eliminate tumor es
AB#3662 · JMKX007129 is a next generation of androgen receptor inhibitor targeting N-terminal domain for the t
AB#3697 · Application of mechanistic preclinical PK/PD/efficacy modeling to support combination strategy for A
AB#3744 · A conditionally-active, dual-targeting TCE with superior tumor selectivity for the treatment of soli
AB#3747 · AZD5305, a PARP1 selective inhibitor, exhibits antitumor effects and stimulates immune response in h
AB#3786 · Preclinical validation of the antitumor activity and safety of M0324, a novel MUC-1 conditional CD40
AB#3802 · Phosphonate-antibody-drug conjugates, a novel immunostimulatory class of ADCs driving inside-out act
AB#3824 · MGT-1141, an antibody-drug-conjugate targeting DLL3 positive cancers
AB#3825 · Highly potent inhibitors of RAD51, with first-in-class potential, targeting HR-proficient cancers
AB#3837 · ZMS-4426, an oral degrader of SMARCA2 shows potent anti-tumor activity, but variant selectivity agai
AB#3841 · Noninvasive artificial intelligence system for prediction of lenvatinib based therapeutic regimens r
AB#3842 · Preclinical osimertinib-resistant mouse models for advancing third-generation EGFR-TKI drug developm
AB#3847 · Leveraging PR-isometric guided deep learning to decode CT-based tumor heterogeneity and enhanced NSC
AB#3860 · HDP-103, a PSMA targeting amanitin-based ADC, is efficacious even in difficult to treat patient deri
AB#3870 · Extrachromosomal circular DNA-mediated NOSIP amplification drives OXPHOS-dependent metastasis in hep
AB#3912 · Self-supervised learning defines a universal biomarker of malignancy in platelet RNA
AB#3920 · Preclinical characterization and evaluation of JSB462 (Luxdegalutamide), a novel AR degrader, and it
AB#3932 · Prediction of gene expression and molecular pathway activity from H&E whole slide images in non-
AB#3963 · The PARP1-selective inhibitor and trapper saruparib achieves extended PARP1 target engagement in

AB#3997 · Inferring transcriptomic programs from circulating tumor DNA methylation signatures in small cell lu

AB#4033 · Prostate cancer chronotherapy: Influence of treatment timing on radiation efficacy and quality of li

AB#4035 · Targeting solid tumors with pH-dependent dual-specific TCEs: First-in-human development of CT-202

AB#4049 · Fragmentomic analysis of cfDNA WGS at regulatory regions generates gene-level expression-like traits

AB#4086 · Deciphering the promotional determinants of esophageal cancer in countries with varying incidence

AB#4095 · Lurbinectedin plus atezolizumab vs durvalumab maintenance in ES-SCLC: A comparative clinical and eco

AB#4136 · Targeting cyclin K-CDK12 synergizes with ATR inhibition by limiting RPA chromatin loading in triple-

AB#4175 · AZD6750, a CD8α-guided IL-2 immunocytokine effectively combines with rilvegostomig, a PD-1/TIGI

AB#4217 · Structural proteomics and AI powers PROTAC rational design

AB#4226 · Age-related p16 epimutation is a targetable driver of Kras-mutant lung cancer

AB#4261 · Early life exposures and cancer in adulthood: World Cancer Research Fund International’s lifec

AB#4262 · BH-30643, a novel macrocyclic non-covalent, mutant-selective EGFR inhibitor, addresses the resistanc

AB#4298 · Development and evaluation of a MIRAI 5-year risk model with a breast cancer polygenic risk score

AB#4332 · Development of CLIO-8221: A HER2-targeted multi-payload ADC to address ADC resistance

AB#4344 · Enhanced delivery and activity of a novel antibody-drug conjugate, PF-08052667, for treatment of non

AB#4349 · Development and validation of a standardized CELLSEARCH® assay for real-time monitoring of pros

AB#4354 · Discovery and characterization of a selective p300 degrader reveals broad anti‑tumor activity

AB#4386 · Design and synthesis of highly efficacious CRBN-based pan-KRAS degraders targeting cancers with KRAS

AB#4398 · Expression profile of therapeutic target CDH17 in gastric cancer

AB#4415 · BCG024: A novel DLL3×CD3×4-1BB trispecific T cell engager enhances T cell persistence and

AB#4431 · Genomic Relational Privacy in AI Era: a scoping review

AB#4453 · Sequential senescence-escape cycles drive genomic heterogeneity and osimertinib resistance in EGFR-m

AB#4488 · Characterization of second-generation AUTOTACs targeting the androgen receptor for castrate-resistan

AB#4519 · The breast cancer survivorship experience of Korean American women: A qualitative study

AB#4548 · DNA methylation differentiates early-stage lung adenocarcinoma cells-of-origin with distinct smoking

AB#4553 · Generative AI improves breast cancer genomic subtype prediction from histology images

AB#4556 · ZW439, a novel CLDN18.2-targeting pan-RAS inhibitor antibody drug conjugate for the treatment of RAS

AB#4569 · Genome-wide CRISPR screening reveals a PKA-driven resistance mechanism to metformin for oral cancer

AB#4605 · Targeting metabolic vulnerabilities in basal-like breast cancer

AB#4665 · Development of a lipid nanoparticle formulation of the bifunctional PARP and HDAC inhibitor kt-3283

AB#4667 · Integrated organoid screening approaches enable preclinical assessment of protein degrader efficacy

AB#4754 · First target disclosure for the preclinical development of ATNM-400, a first-in-class actinium-225 r

AB#4773 · SPOP drives AR-V7-mediated ARPI resistance in prostate cancer

AB#4813 · Preclinical evaluation of [177Lu]Lu-PSMA-617 and [225Ac]Ac-PSMA-617 in mice bearing castration-resis

AB#4827 · Predictors of antidepressant use in older adults after pancreatic cancer diagnosis: A SEER-Medicare

AB#4862 · The HER2-targeting dual-payload antibody-drug conjugate combining a topoisomerase I inhibitor and a

AB#4864 · RenNano platform enables efficient discovery of fully human VHH antibodies

AB#4906 · Engineering isogenic models harboring resistance mechanisms to the latest-generation EGFR inhibitor

AB#4908 · The mesenchymal state drives stemness and limits differentiation in glioblastoma

AB#4910 · Targeting PGK1 enhances enzalutamide efficacy in resistant prostate cancer

AB#4917 · BCG026: FAP × GPC1 bispecific ADC - A novel targeting approach for stromal and tumor cells in p

AB#4944 · Development of ZW418, a biparatopic PTK7-targeting antibody-drug conjugate incorporating a novel pan

AB#4953 · Rinzimetostat blockade of PRC2 activity, a key mechanism of treatment resistance, improves response

AB#4956 · Preclinical study of BCG044, a novel bispecific ADC targeting EpCAM and HER3 for the treatment of co

AB#4960 · NRX-0305, an orally bioavailable, CNS penetrant pan-mutant BRAF degrader demonstrates robust efficac

AB#4986 · BCG045: A first-in-class bispecific ADC targeting TROP2 and MUC1 demonstrates promising tumor effica

AB#5026 · TRI-611, a development stage molecular glue degrader of ALK for the treatment of ALK-positive NSCLC

AB#5083 · Dual dependency of large cell neuroendocrine carcinoma on Ras and ASCL1 oncogenic pathways

AB#5103 · Examining the effect of second-generation antiandrogens in androgen receptor-overexpressing prostate

AB#5125 · Rinzimetostat, an allosteric EED inhibitor with best-in-class properties for the treatment of prosta

AB#5131 · An MCP-enabled AI agent for automated multimodal genomics analysis in the Isabl Platform

AB#5140 · A pan-RASi antibody-drug conjugate platform with high activity in RAS-mutant cancers

AB#5164 · RAS(ON) inhibition in both cancer and immune cells by daraxonrasib drives anti-tumor immunity

AB#5167 · AI-based detection and scoring of TROP2 expression in IHC-stained NSCLC specimens

AB#5171 · GP CoPilot: An AI-enhanced agent for cancer research

AB#5206 · Clinical-grade quality control and stain harmonization enhancement in whole-slide images of lung can

AB#5259 · Advancing precision oncology through tumor digital twins: A versatile ViT-determined margin-consiste

AB#5261 · Benchmarking gene expression foundation models on bulk RNA-Seq data

AB#5278 · RCZY-698: An orally bioavailable, highly potent, and selective reversible KRAS^G12V (ON)-s

AB#5294 · Preclinical development of LUA005: A differentiated bivalent EGFR/cMET bispecific ADC displays stron

AB#5299 · ABSK211, a highly potent and orally available pan-KRAS inhibitor, demonstrates robust antitumor effi

AB#5300 · Diversity-oriented dpADC discovery with high throughput dual-conjugation platform and predictive res

AB#5302 · Rapid curation of colon cancer cohorts using on-site peta-scale language model for MSI classificatio

AB#5312 · PortrAIgent: Co-scientist agent for end-to-end spatial transcriptomics discovery

AB#5321 · VGL: Vision-Gene-Language multimodal LLM integrating histopathology and gene expression for cell typ

AB#5327 · Preclinical characterization of a potent and selective Werner helicase (WRN) inhibitor with activity

AB#5348 · Artificial intelligence-based spatial analysis of the local tumor microenvironment in relation to c-

AB#5360 · CD99 homophilic signaling between tumor-associated macrophages and glioblastoma cells regulates resp

AB#5395 · Targeting cholesterol pathways in p53 deficient head and neck cancers

AB#5468 · Synergistic integration of nanobodies and a specialized linker library: A novel radionuclide drug co

AB#5522 · DXC011, a novel dual-payload antibody-drug conjugate targeting folate receptor alpha

AB#5534 · AT06 is a bispecific antibody drug conjugate targeting DLL3 and SEZ6 with potent activity in small c

AB#5542 · Trispecific TCE with second signal boosts solid tumor response efficacy, durability and safety

AB#5591 · Validation of the ViewsML vIHC platform for biomarker classification and intensity binning: A pilot

AB#5612 · RCZY-690: A tri-complex molecular glue pan-RAS (ON) inhibitor exhibiting best-in-class potential for

AB#5625 · A novel synergistic dual-payload FRα ADC (CTPH-08) that can potentially offer benefits for low

AB#5654 · Preclinical characterization of ABSK211: A highly potent, orally bioavailable and selective pan-KRAS

AB#5672 · Discovery of QLS1303, a potent and selective KIF18A inhibitor with robust anti-tumor activity in CIN

AB#5701 · A novel anti-CD3×CD28×STEAP1 tri-specific T-cell engager with enhanced and durable antitum

AB#5704 · Whole-genome doubling induces chromosomal instability to shape the tumor-immune microenvironment and

AB#5711 · Exploration of novel E3 ligase to support targeted protein degradation drug discovery

AB#5717 · Novel syngeneic models for evaluating therapies targeting EGFR^L858R/T790Mand EGFR^L85

AB#5747 · Digital PCR-based plasma DNA methylationassayfor noninvasive molecular subtyping of small cell lung

AB#5758 · PD-L1-dependent 4-1BB costimulation enhances anti-tumor efficacy and T cell persistence as monothera

AB#5765 · RCZY-869: A highly potent, selective, and orally bioavailable covalent KRAS^G12D (ON-state

AB#5774 · QLS1403, a novel and potent PARG inhibitor with robust anti-tumor efficacy in homologous recombinati

AB#5782 · Preclinical development of LUA006: A bispecific EGFR/B7-H3 ADC with dual payloads to address tumor h

AB#5791 · MAC-8001: A KRAS-targeting molecular glue-antibody conjugate with robust antitumor activity in KRAS-

AB#5793 · Preclinical characterization of HY809382, a highly potent and orally bioavailable PRC2 PROTAC, for t

AB#5810 · Novel DLL3 x B7H3 bispecific ADC demonstrated superior efficacy in preclinical studies

AB#5819 · BSI-128 (AK2024) enhances trastuzumab function and potentiates trastuzumab-deruxtecan activity acros

AB#5847 · Fragment-recombination design of a dual VEGFR2/TIE2 inhibitor with sarcoma-selective cytotoxicity

AB#5849 · Learning spatial transcriptomic patterns from whole-slide images with a cancer-scale foundation mode

AB#5857 · ALK101sc, a novel afucosylated bispecific antibody targeting EGFR and c-MET with common light chain

AB#5872 · Mechanistic insights into PLK1 target inhibition in ovarian cancer: Functional suppression and PROTA

AB#5890 · Targeting Beta-catenin in colorectal cancer: Novel molecular glue drug candidates by Coltac’s BOND+

AB#5939 · CXB-7138, A novel GSPT1/ZFP91 dual molecular glue degrader, for targeted treatment of pancreatic duc

AB#5942 · A systematic analysis on patients with NSCLC transformation to SCLC

AB#5964 · A STING-boosted lipid nanoparticle mRNA vaccine for therapeutic cancer vaccination

AB#5965 · WuXiTecan2: A hydrophilic exatecan linker-payload for dual-payload ADC discovery

AB#5970 · Clinical impact of intraepithelial versus stromal immune cells in kidney cancer

AB#5992 · Molecular characteristics of MP0712, a clinical stage ²¹²Pb-based Radio-DARPin candid

AB#6009 · Machine learning and structure-guided discovery of EP300-selective, orally bioavailable degraders fo

AB#6022 · VHH nanobody-masked conditionally active CDH17 T cell engager for colorectal cancer

AB#6052 · A biparatopic DLL3-targeting trispecific T-cell engager delivered by mRNA-LNP drives potent anti-tum

AB#6053 · Monitoring androgen receptor and neuroendocrine marker expression dynamics in CTCs in patients with

AB#6058 · HY809382, a PRC2 degrader with best-in-class properties, demonstrates efficacy across multiple tumor

AB#6106 · Discovery of FX-111, a first-in-class heterobifunctional degrader of transcriptionally active androg

AB#6116 · Integrating spatial transcriptomics with MRI reveals distinct radio-spatial genomic profile concorda

AB#6123 · Clinical validation of a multi-gene blood test for kidney cancer screening and stratification

AB#6129 · RBM39 degrader anticancer activity against neuroblastoma: CDKN2A/B deletion as a biomarker

AB#6133 · Microbiome foundation modeling of cancer: MiFM-derived continuous trajectories and risk clocks for p

AB#6152 · Novel non-CRBN based molecular glue identification and corresponding E3 ligase target deconvolution

AB#6153 · Epigenomic liquid biopsy molecular lung subtyping and real-world (RW) patient outcomes in advanced N

AB#6227 · Baseline peripheral blood scRNA-seq AI estimator framework predicts solid-tumor response and adverse

AB#6277 · Investigating a Wilms tumor DNA methylation signature in liquid biopsies

AB#6287 · Comprehensive preclinical in vivo oncology platform for rational drug candidate nomination

AB#6325 · Agentic AI for RNA-Seq: From workflow automation to actionable insights

AB#6346 · Mapping PSMA-617 sensitivity in prostate cancer PDX models to enable combination therapy and resista

AB#6372 · Automated robust normalization and context-aware rescue of TReg cells from multiplex immunofluoresce

AB#6409 · Characterization of functional estrogen receptor (ER) dependence via comprehensive epigenomic liquid

AB#6469 · Evaluation of large language models for automated clinical trial matching in oncology

AB#6491 · Ensuring pathologist alignment to safeguard data integrity in multi-centre oncology IVD/CDx clinical

AB#6513 · Rational discovery of novel molecular glues

AB#6571 · Development of an LLM framework for analysis of heterogeneous breast cancer patients genomic reports

AB#6631 · Large language model-based triage of Hematology/Oncology patient messages: Performance, safety, and

AB#6636 · Exploiting ketone body metabolism as a therapeutic vulnerability in prostate cancer

AB#6651 · Improving the utility of the single-cell pediatric cancer atlas through updated cell type annotation

AB#6654 · A novel bispecific antibody-drug conjugate targeting CEACAM5 and CDH17 exhibits potent anti-tumor ac

AB#6673 · Multi-omic analysis nominates SPP1-IL10 axis as a novel immunotherapeutic target in gastric peritone

AB#6697 · Feasibility of a survivorship app for black prostate cancer survivors: Results from a 12-week mHealt

AB#6742 · The metabotropic Glutamate receptor-1 is a glutamatergic checkpoint that integrates with TCR to augm

AB#6750 · Development of a virtual Cyclin E1 biomarker using Deep Learning from H&E slides for predicting

AB#6751 · BPTF regulates androgen receptor activity in prostate cancer

AB#6798 · Establishing the mechanistic link between chemotherapy response and Hippo-YAP signaling in ovarian c

AB#6819 · An AI-guided biparatopic DLL3-targeting ADC demonstrates enhanced preclinical efficacy

AB#6836 · An AI-driven multimodal workflow for enhancing late-phase clinical trial outcome prediction

AB#6838 · A translational framework for high-plex spatial profiling and complexity reduction toward diagnostic

AB#6841 · Loxl2 drives neutrophil-mediated immune evasion and resistance to anti PD-1 therapy in murine melano

AB#6897 · Lurbinectedin alters EWS::FLI1 binding to chromatin to poison transcription

AB#6903 · Loss of SIRT3 promotes metabolic and epigenetic dysregulation in aggressive prostate cancer

AB#6927 · Whole-slide image and clinical feature integration for superior prostate cancer risk stratification

AB#6953 · Discovery of a selective molecular glue degrader of CCNE1 for the treatment of CCNE1-amplified solid

AB#7011 · A healthcare system scale multimodal whole patient temporal foundation model

AB#7021 · Novel therapeutic opportunities in POU2F3 transcription factor-driven small cell lung cancer

AB#7063 · Engaging communities in cancer research: Outcomes from the CaRE² health center’s 20

AB#7089 · Limited efficacy of HER3-DXd in colorectal cancer PDX models reveals molecular resistance mechanisms

AB#7134 · Automated cohort extraction from real-world oncology data using adaptive LLM-based agentic systems f

AB#7143 · Rilvegostomig elicits greater immune activation and tumor inhibition than clinically approved anti-P

AB#7162 · VS-7375: An oral, selective KRAS G12D dual ON/OFF inhibitor with potent anti-tumor activity as a sin

AB#7167 · New approach methodologies for risk assessment and functional evaluation of immuno-oncology drug can

AB#7194 · Determinants of sacituzumab govitecan therapeutic response in breast cancer models

AB#7268 · Preclinical characterization of NEO-811, a novel molecular glue degrader of ARNT for the treatment o

AB#7275 · Novel application of the iCCaRE consortium virtual reality assistant (ViRA) to support Black men at

AB#7287 · Identification of first in class selective ARID1B degraders

AB#7315 · Synergistic disruption of KRAS and FAK pathways: A preclinical pipeline for PDAC therapy optimizatio

AB#7325 · Path2Prot offers a new way for breast tumor subtyping and treatment response prediction from

AB#7335 · First-in-class potent and selective oral KAT6A degrader development candidate, PRT13722, drives comp

AB#7351 · CLSP-5282, a first-in-class T cell engager targeting KRas^G12V mutant peptide presented on

AB#7362 · Discovery of first-in-class YTHDC1 small molecule inhibitors for the treatment of MYC-driven cancers

AB#7400 · Pharmacological integration of CD3 and CD2 signaling triggers formation of a CD2 corolla that boosts

AB#7424 · GFRAL is not required for PDAC tumor development and TME immune cell suppression

AB#7440 · Leveraging E2 ligases for induced proximity and modulation of novel cancer-relevant targets and neos

AB#7465 · Allele frequency variation in people of European and admixed African ancestry in the United States d

AB#7469 · Development and characterization of a patient-derived liver organoid biobank for toxicology and func

AB#7563 · Lead Bioaccumulation Drives Genomic Instability and Apoptotic Resistance in Human Breast Cancer

AB#7566 · Hypoxia reveals a polyaneuploid cancer cell phenotype with features implicated in tumor escape and e

AB#7626 · Cysteine oxidation is required for brain metastasis in lung cancer

AB#7635 · Tumor specific induction of surface calreticulin by doxorubicin in pancreatic ductal adenocarcinoma

AB#7676 · Immune cell profile changes in patients treated with tarlatamab for extensive stage small cell lung

AB#7679 · CNTF governs exercise-induced myofibroblast reversion in prostate cancer

AB#7715 · ZW427, a Ly6E-targeting antibody drug conjugate bearing a novel pan-RAS inhibitor payload for the tr

AB#7771 · Beyond bulk: Resolving RNASeq/mass spectrometry/IHC discrepancies with multiplexed spatial profiling

AB#7779 · BBO-11818: An orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) i

AB#7781 · Trace metal signatures in non-small cell lung cancer: A pilot study of patients attended at Mount Si

AB#7785 · Deep learning-based survival prediction of post-operative GBM patients via multimodal radiomic pheno

AB#7816 · Benefit of combining DLL3 targeted alpha therapy with standard of care in preclinical small cell lun

AB#7836 · Intestinal inflammation triggersPOLE^P286^R-driven ultramutated colorecta

AB#7881 · LLM-based extraction of immunotherapy toxicities reveals severity-dependent effects on overall survi

AB#7886 · Charles: A self-critical agentic AI drug discovery analyst for cancer

AB#7898 · Ferroptosis induction synergizes with KRAS inhibitors in KRAS-mutant lung adenocarcinoma

AB#7994 · Source discipline matters: Guideline anchored large language model outperforms Open Evidence for dec

AB#8039 · Defining and targeting drivers of lineage plasticity in stem cell-like prostate cancer

AB#8045 · CertisAI Assistant: An agentic AI platform for dynamic preclinical oncology model selection

AB#8066 · Targeted polymeric nanoconjugates for BBB penetration and time specific delivery of PDL1 blocking sm

AB#8093 · Preclinical evaluation of armored DLL3 biepitope compound nanobody CAR T cells

AB#8100 · Single-cell liquid biopsy profiling in mCRPC receiving PSCA-targeted CAR-T cell therapy

AB#8216 · Tambiciclib (SLS009), a CDK9 inhibitor, promotes apoptosis and suppresses MCL-1 levels in AML cell l

AB#8235 · Single-cell transcriptomic characterisation reveals pathway determinants of bipolar androgen therapy

AB#8250 · Predicting TCGA molecular subtypes of gastric cancer from H&E whole-slide images using a weakly

AB#8252 · A novel AI-engineered biparatopic DLL3/CD3 T cell engager demonstrates potent preclinical efficacy a

AB#8267 · Targeting phospholipase D1 overcomes platinum resistance and enhances cisplatin efficacy in ovarian

AB#8318 · RUNX1T1 as an early driver in treatment-induced neuroendocrine transdifferentiation

AB#8340 · A novel BRD4 degrader-HER2-targeting antibody-drug conjugate (DAC) overcomes trastuzumab deruxtecan

AB#8343 · Label free virtual HE from 3D holotomography enables reliable nuclear and microanatomical readouts i

AB#8351 · Sex-specific plasma-immune architectural differences in bone marrow predicts overall survival in mul

AB#8371 · Mechanistic dissection of ABI1 as DNA-binding transcriptional regulator in cancer cells

AB#8431 · High-throughput capillary immunoassays enable precise quantitation of protein degrader potency and k

AB#8438 · 3D holotomography-enabled virtual multiplexed staining of thick medical kidney tissue for comprehens

AB#8443 · PDXovo: Avian embryos as hosts for rapid and quantitative modelling of immunotherapy response

AB#8460 · Depth prediction in superficial esophageal cancer using a foundation model from endoscopic images

AB#8485 · Metabolic crosstalk between fatty acid oxidation and glycolysis underlies glioblastoma viability

AB#8619 · Pharmacological disruption of YAP1/TEAD and NF-kappa B crosstalk suppresses prostate cancer

AB#8659 · Multi-agent AI orchestration for temporal-aware extraction of social determinants of health from uns

AB#8689 · Real world prediction and biological characterization of sotorasib sensitivity using multimodal AI a

AB#8696 · Multimodal AI predicts immune checkpoint inhibitor response from clinically available inputs and who

AB#8714 · ACR335, a novel cMET/EGFR bispecific dual-payload antibody-drug conjugate, demonstrates potent and b

AB#8739 · Tumor-localized monoclonal antibody targeting 4-1BB for superior safety and efficacy in cancer treat

AB#8746 · DrBioRight: an AI research assistant for cancer data analysis

AB#8780 · Humans cannot live by artificial intelligence (AI) alone

AB#9605 · Phase 1 study of ARV-393, a PROTAC BCL6 degrader, as monotherapy in patients with advanced non-Hodgk

AB#9636 · The first report of patients with solid tumors treated with LP-118, a novel Bcl-2/Bcl-xL dual inhibi

AB#9721 · Towards a platform PBPK-QSP model for first-in-human dose selection of GenSci139, a potential best-i

AB#9728 · A phase 1b/2 trial of gemcitabine, cisplatin, nab-paclitaxel, and tislelizumab (GENTIS) in patients

AB#9733 · Preliminary phase 1a/1b results of GIGA-564, a novel intratumoral Treg-depleting anti-CTLA-4 antibod

AB#9769 · Preliminary safety, pharmacokinetics and pharmacodynamics of SGR-3515, a Wee1/Myt1 dual inhibitor fr

AB#9780 · LYC001, a high-affinity hierarchical assembly for lymph node-targeted IL-2 immunotherapy: Preclinica

AB#9789 · Error-corrected plasma whole-genome sequencing for personalised and tumor-agnostic minimal residual

AB#9796 · Phase I study of ERY974 in patients with glypican-3 (GPC-3)-positive advanced solid tumors

AB#9847 · Irreversible electroporation (IRE) with intratumoral CD40 antibody increases T-cell reactivity to pe

AB#9848 · Phase I/II clinical trial of CVL006 combination therapy in advanced solid tumors

AB#9850 · A first-in-human, intra-tumoral AAV2-RUNX3 gene therapy (RX001) for advanced KRAS-mutant NSCL

AB#9865 · A first-in-human (FIH), Phase 1/2, dose-escalation and dose-optimization study of central nervous sy

AB#9872 · Whole body PBPK/PD modeling to support first-in-human dose selection for GenSci140, a potential best

AB#9892 · Identifying mechanisms of immune suppression in KRAS-inhibitor resistance in NSCLC

AB#9905 · First-in-human study of oral PARG inhibitor SYN608 in advanced solid tumors

AB#9909 · Phase Ib study of POLQ inhibitor SYN818 combined with olaparib in advanced solid tumors

AB#9925 · Ribonucleotide reductase inhibition triggers ferroptosis in genetically defined NSCLC

AB#9927 · First-in-human study of neoadjuvant regional delivery of the TLR9 agonist Nelitolimod via pressure e

AB#9941 · Discovery and characterization of ABK-EGFR-1, a 4^th generation EGFR C797S Inhibitor with

AB#9970 · An integrated DNA methylation-based and multidimensional risk factor model for predicting breast can

AB#9975 · NTS071-101: A phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, and prelimina

AB#9998 · Pilot study of an implantable microdevice for in situ evaluation of drug response in patients

AB#10007 · Investigator-initiated phase I trial of an oligonucleotide therapeutic targeting long noncoding RNA

AB#10028 · A Phase 1/2 study of BDC-4182, a claudin18.2-targeting next generation immune-stimulating antibody c

AB#10045 · Mechanisms of acquired resistance following dual EGFR/MET inhibition in MET-amplified EGFR TKI-resis

AB#10082 · HZ-V055, an oral, highly potent pan-Ras molecular glue inhibitor demonstrated robust potency in Ras<

AB#10088 · Phase 1 study of HRS-6209, a highly selective CDK4 inhibitor, in patients with advanced solid tum

AB#10090 · Camu camu plus nivolumab/ipilimumab (N/I) as first-line therapy for metastatic renal cell carcinoma

AB#10123 · FiREBOLT: A phase 1 study evaluating radioligand therapy with LY4337713 in adults with select FAP+ s

AB#10132 · Preliminary results from a first-in-human phase I/II study of JS212, an EGFR/HER3-targeted bispecifi

AB#10186 · Safety, dosimetry, and RP2D determination of Ga‑68‑NGUL and Lu‑177‑DGUL (poc

AB#10221 · Preliminary results from a Phase 1a/b dose-escalation and expansion trial of the pan-RAF-MEK molecul

AB#10234 · Daraxonrasib monotherapy as first-line (1L) treatment for patients with metastatic pancreatic adenoc

AB#10242 · Intralesional PD-1 blockade for oral cancer prevention: First-in-class phase 1 trial

AB#10246 · OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus

AB#10261 · Preliminary clinical results of TAVO412, an anti-EGFR/cMET/VEGF multispecific antibody, in patients

AB#10271 · Prostate cancer phenotypes determined from circulating tumor DNA associate with outcomes to ¹⁷⁷

AB#10283 · A phse 1 study of CAN2109, a novel,long-acting, tumor-retained, immunoegenic cell death inducer

AB#10295 · OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX

AB#10332 · Preliminary results from the first-in-human study of MK-2010, a PD-1×VEGF bispecific antibody

AB#10338 · AGB101, a first-in-class Vβ17 x DLL3 bispecific antibody, selectively redirects Vβ17 T mem

AB#10356 · Phase 1/2a open-label clinical trial evaluating VBC101, an EGFR and cMET targeted bi-specific antibo

AB#10358 · First-in-human study of the IL-12 Prodrug KGX101 demonstrates tumor-microenvironment specific activa

AB#10362 · Intracranial activity of ZL-1310, a DLL3-targeted ADC, in patients with previously treated extensive

AB#10371 · Ph1b evaluation of ADG126 (muzastotug, an anti-CTLA-4 masking antibody) pembrolizumab (Pembro) IO do

AB#10376 · An orally bioavailable AR-NTD degrader that bypasses LBD-dependent resistance and prevents AR-V7-med

AB#10380 · Preliminary results from the phase 1b/2, open-label, multi-center study of ZL-1310, a DLL3-targeted

AB#10381 · First-in-human (FIH) study of EVM16, a personalized mRNA neoantigen vaccine, as monotherapy and comb

AB#10387 · RASolve 301: A Phase 3 study of daraxonrasib (RMC-6236) vs. docetaxel in patients with previously tr

AB#10416 · Immune escape via myeloid-derived suppressor cells in solid tumor cancer patients treated with ancho

AB#10444 · Phase I study of TROP2 CAR engineered IL-15-transduced cord blood-derived NK cells in advanced solid

AB#10510 · Interim results of a phase I clinical trial evaluating Fas ligand (FasL) blocking antibody M3T01 in

AB#10515 · First-in-human, phase I/II study of BPI-572270, an oral RAS(ON)multi tri-complex inhibit

AB#10521 · BPI-585771: A novel, potent pan-KRAS degrader with potent in vitro and in vivo efficac

AB#10536 · SON-1010 (IL12-F_HAB) synergizes with trabectedin in advanced soft-tissue sarcoma

AB#10545 · VBC229: A novel DLL3-targeting biparatopic T-cell engager-topoisomerase I inhibitor fusion molecule

AB#10589 · Preliminary results of first-line botensilimab (BOT) and balstilimab (BAL) optimization in microsate

AB#10591 · VS-7375, a non-covalent dual ON/OFF KRAS^G12Dinhibitor, displays superior activity to ON-

AB#10592 · Updated results from a first-in-human phase 1,2 study of ACE-106, a highly selective and potentially

AB#10598 · First in human phase 1 study of D3S-002, a purposely designed ERK1/2 inhibitor, in advanced solid tu

AB#10606 · VRN110755: A next-generation non-covalent EGFR tyrosine kinase inhibitor for EGFR-mutated NSCLC

AB#10615 · First-in-human phase I study of UCL70802, a LACO-Stim armored Anti-CD70 CART cell therapy, in patien

AB#10651 · P65-047, a novel TEAD degrader, overcomes KRAS inhibitor resistance through Hippo pathway disruption

AB#10663 · The p53-Reprimo-Hippo-YAP-p73 pathway: An extrinsic apoptosis mechanism for tumor suppression

AB#10685 · Active RAS inhibition intercepts pancreas cancer in mice

AB#10693 · Global first-in-human (FiH) monotherapy dose escalation trial of BAY2862789, a diacylglycerol kinase

AB#11036 · Obrixtamig (BI 764532) in patients with relapsed/refractory delta-like ligand 3 (DLL3) high-expressi

AB#11041 · Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (Pts) with metastatic

AB#11042 · Quantitative Systems Pharmacology (QSP) enables research and translation of AMP01, a novel next gene

AB#11050 · Discovery of Helicon peptides that selectively degrade the agonist-bound androgen receptor (AR^O

AB#11064 · First-in-human trial of ²²⁵Actinium-DOTA-daratumumab, an alpha-emitting radioimmunotherap

AB#11086 · Impact of first-line (1L) amivantamab-lazertinib vs osimertinib on second-line (2L) progression-free

AB#11092 · A first-in-class TAU-1-directed androgen receptor (AR) and AR-V7 degrader recruits DDB1-CUL4-RBX1 E3

AB#11128 · DLL3 expression on circulating tumor cells predicts response to bispecific antibody tarlatamab

AB#11152 · Dose escalation and expansion of nivolumab plus relatlimab (NIVO + RELA) in solid tumors in RELATIVI

AB#11163 · RELATIVITY-104 Part 2: translational analyses in the programmed death ligand 1 (PD-L1) ≥ 1% an

AB#11204 · Phase I study of intratumoral microdevices reveals heterogenous immune and apoptotic responses acros

AB#11212 · A phase I study of the type II ROS1 TRK inhibitor ANS03 in ROS1 fusion-positive lung cancers

AB#11215 · Discovery and identification of SHR-RAS001: A structurally novel, highly potent tri-complex RAS<s

AB#11220 · JNJ-95437446: Discovery and preclinical characterization of an amivantamab-based EGFR/MET-ADC for so

AB#11227 · Phase I trial of CRD3874-SI, a systemically administered third generation allosteric STING agonist,

AB#11239 · PET imaging and response to amivantamab treatment of non-small cell lung cancer xenografts

AB#13068 · Backfilling in early-phase oncology trials: A patient perspective on dose-finding innovation

AB#13081 · Care and treatment of the LGBTQ+ community in the present hostile political environment?

AAI Internal Wiki

探索

References Index

References · 469 abstracts cited in narrative

關係圖譜